These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 17409285)

  • 1. Trapping of a nonpeptide ligand by the extracellular domains of the gonadotropin-releasing hormone receptor results in insurmountable antagonism.
    Kohout TA; Xie Q; Reijmers S; Finn KJ; Guo Z; Zhu YF; Struthers RS
    Mol Pharmacol; 2007 Aug; 72(2):238-47. PubMed ID: 17409285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges and opportunities of trapping ligands.
    Szkudlinski MW
    Mol Pharmacol; 2007 Aug; 72(2):231-4. PubMed ID: 17522183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overlapping, nonidentical binding sites of different classes of nonpeptide antagonists for the human gonadotropin-releasing hormone receptor.
    Betz SF; Reinhart GJ; Lio FM; Chen C; Struthers RS
    J Med Chem; 2006 Jan; 49(2):637-47. PubMed ID: 16420049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of nonpeptide antagonist binding to the human gonadotropin-releasing hormone receptor: Implications for structure-activity relationships and insurmountable antagonism.
    Sullivan SK; Hoare SR; Fleck BA; Zhu YF; Heise CE; Struthers RS; Crowe PD
    Biochem Pharmacol; 2006 Sep; 72(7):838-49. PubMed ID: 16930559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracellular loop 3 (EL3) and EL3-proximal transmembrane helix 7 of the mammalian type I and type II gonadotropin-releasing hormone (GnRH) receptors determine differential ligand selectivity to GnRH-I and GnRH-II.
    Li JH; Choe H; Wang AF; Maiti K; Wang C; Salam A; Chun SY; Lee WK; Kim K; Kwon HB; Seong JY
    Mol Pharmacol; 2005 Apr; 67(4):1099-110. PubMed ID: 15635044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor.
    Sasaki S; Cho N; Nara Y; Harada M; Endo S; Suzuki N; Furuya S; Fujino M
    J Med Chem; 2003 Jan; 46(1):113-24. PubMed ID: 12502365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice.
    Nakata D; Masaki T; Tanaka A; Yoshimatsu M; Akinaga Y; Asada M; Sasada R; Takeyama M; Miwa K; Watanabe T; Kusaka M
    Eur J Pharmacol; 2014 Jan; 723():167-74. PubMed ID: 24333551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential impact of intracellular carboxyl terminal domains on lipid raft localization of the murine gonadotropin-releasing hormone receptor.
    Navratil AM; Farmerie TA; Bogerd J; Nett TM; Clay CM
    Biol Reprod; 2006 May; 74(5):788-97. PubMed ID: 16371589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular interactions of nonpeptide agonists and antagonists with the melanocortin-4 receptor.
    Fleck BA; Chen C; Yang W; Huntley R; Markison S; Nickolls SA; Foster AC; Hoare SR
    Biochemistry; 2005 Nov; 44(44):14494-508. PubMed ID: 16262250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in the human gonadotropin-releasing hormone receptor: insights into receptor biology and function.
    Bédécarrats GY; Kaiser UB
    Semin Reprod Med; 2007 Sep; 25(5):368-78. PubMed ID: 17710733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Species selectivity of nonpeptide antagonists of the gonadotropin-releasing hormone receptor is determined by residues in extracellular loops II and III and the amino terminus.
    Reinhart GJ; Xie Q; Liu XJ; Zhu YF; Fan J; Chen C; Struthers RS
    J Biol Chem; 2004 Aug; 279(33):34115-22. PubMed ID: 15155770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency.
    Schottelius M; Berger S; Poethko T; Schwaiger M; Wester HJ
    Bioconjug Chem; 2008 Jun; 19(6):1256-68. PubMed ID: 18510351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of the binding mode of thienopyrimidinedione antagonists to the human gonadotropin releasing hormone receptor using structure-activity relationships, site-directed mutagenesis, and homology modeling.
    Betz SF; Lio FM; Gao Y; Reinhart GJ; Guo Z; Mesleh MF; Zhu YF; Struthers RS
    J Med Chem; 2006 Oct; 49(21):6170-6. PubMed ID: 17034124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amiloride derivatives and a nonpeptidic antagonist bind at two distinct allosteric sites in the human gonadotropin-releasing hormone receptor.
    Heitman LH; Ye K; Oosterom J; Ijzerman AP
    Mol Pharmacol; 2008 Jun; 73(6):1808-15. PubMed ID: 18344315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracellular loop 3 (ECL3) and ECL3-proximal transmembrane domains VI and VII of the mesotocin and vasotocin receptors confer differential ligand selectivity and signaling activity.
    Cho HJ; Moon MJ; Kwon HB; Hwang JI; Seong JY
    Gen Comp Endocrinol; 2008 Mar; 156(1):71-82. PubMed ID: 18158152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dominant-negative action of disease-causing gonadotropin-releasing hormone receptor (GnRHR) mutants: a trait that potentially coevolved with decreased plasma membrane expression of GnRHR in humans.
    Leaños-Miranda A; Ulloa-Aguirre A; Ji TH; Janovick JA; Conn PM
    J Clin Endocrinol Metab; 2003 Jul; 88(7):3360-7. PubMed ID: 12843188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E-box regulation of gonadotropin-releasing hormone (GnRH) receptor expression in immortalized gonadotrope cells.
    Resuehr D; Wildemann U; Sikes H; Olcese J
    Mol Cell Endocrinol; 2007 Nov; 278(1-2):36-43. PubMed ID: 17928134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relations of successful pharmacologic chaperones for rescue of naturally occurring and manufactured mutants of the gonadotropin-releasing hormone receptor.
    Janovick JA; Goulet M; Bush E; Greer J; Wettlaufer DG; Conn PM
    J Pharmacol Exp Ther; 2003 May; 305(2):608-14. PubMed ID: 12606630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and evaluation of homo-bivalent GnRHR ligands.
    Bonger KM; van den Berg RJ; Heitman LH; IJzerman AP; Oosterom J; Timmers CM; Overkleeft HS; van der Marel GA
    Bioorg Med Chem; 2007 Jul; 15(14):4841-56. PubMed ID: 17517510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptor.
    Miwa K; Hitaka T; Imada T; Sasaki S; Yoshimatsu M; Kusaka M; Tanaka A; Nakata D; Furuya S; Endo S; Hamamura K; Kitazaki T
    J Med Chem; 2011 Jul; 54(14):4998-5012. PubMed ID: 21657270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.